Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet’s disease,...
Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet’s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protocol
About this item
Full title
Author / Creator
Publisher
England: British Medical Journal Publishing Group
Journal title
Language
English
Formats
Publication information
Publisher
England: British Medical Journal Publishing Group
Subjects
More information
Scope and Contents
Contents
IntroductionResearch into novel therapies for rare, immune-mediated inflammatory diseases (IMIDs) faces significant challenges, including small patient populations, complex clinical trial design and difficulties in patient recruitment. Patients with Behçet’s disease (BD), idiopathic inflammatory myopathies (IIM) and IgG4-related disease (IgG4-RD) t...
Alternative Titles
Full title
Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet’s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protocol
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_46dbb89c988848b6bd7bbaf3785230ca
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_46dbb89c988848b6bd7bbaf3785230ca
Other Identifiers
ISSN
2044-6055
E-ISSN
2044-6055
DOI
10.1136/bmjopen-2024-089827
